Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Forest Laboratories
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female outpatients of age 18 years or above
Patients diagnosed with stage 1 or stage 2 essential hypertension
Normal physical examination findings, electrocardiogram (ECG) results and chest x-ray; or abnormal findings judged by the Investigator to be not clinically significant
You may not be if
Secondary hypertension or severe hypertension
Clinically significant cardiovascular disease or heart failure
Clinical significant respiratory disease that would prohibit the use of a beta blocker
A medical contraindication to discontinuing a current antihypertensive therapy
History of Type 1 diabetes mellitus
History of Severe Mental Illness except mild depression
Clareo Health | Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
